Go to contentGo to menuGo to search

THE BIND PROJECT

Bordeaux Initiative for Neurodegenerative Disorders « BIND »

The September 28, 2015


 François Tison the coordinator

BORDEAUX IS IDENTIFIED AS A CENTER OF EXCELLENCE IN THE FIELD OF NEURODEGENERATIVE DISORDERS BY FRENCH GOVERNMENT WITH THE BIND PROJECT

The French government launched in November 2014 the National Plan Neurodegenerative Diseases 2014-2019 which proposed the « Identification of centers of excellence in the field of neurodegenerative disorders ».


With the integration of outstanding skills and infrastructure at a single location, Bordeaux offers an ambitious project based on multi-disciplinary researchers teams in a framework of an excellent research ecosystem.
In this context, the University of Bordeaux, associated with the University Hospital of Bordeaux, present the Bordeaux Initiative for Neurodegenerative Disorders (ND) « BIND ».
BIND will create value by pushing back the frontiers of knowledge. It aims at bounding multiple disciplines and ND, along a continuum from preclinical to clinical research to improve care provision. This patient-centred, centripetal and transdisciplinary initiative for ND will rely on a core of recognized excellence and will promote links with other disciplines.
Researchers associated in BIND project will have a complete environment for exercising their expertise.
BIND is now identified as a center of excellence in the field of neurodegenerative disorders.

TEAMS

The Bordeaux Initiative for Neurodegenerative Disorders (ND) « BIND » is led by the University of Bordeaux, 3rd French multidisciplinary and “The Initiative of Excellence” awarded University (IdEx Bordeaux), associated with the University Hospital of Bordeaux, 3rd regional French CHU in clinical research.
It aims at bounding multiple disciplines and ND, along a continuum from preclinical to clinical research to improve care provision. This patient-centred, centripetal and transdisciplinary initiative for ND will rely on a core of recognized excellence and will promote links with other disciplines.
The core is constituted by leading teams belonging to:
The Bordeaux Neurocampus and cluster of excellence LabEx BRAIN;
The Bordeaux Population Health Research Center (BPH) and Health-Society platform (Cassiopée), cohorts and expertise in clinical research methodology;
The bio-imaging centre-IBIO and clusters of excellence LabEx TRAIL;
Patient care and clinical research infrastructures of the CHU, particularly the emblematic clinical platform of the IMN (IMNc), the MS clinic and the Centre for Clinical Investigation Pharmacology and Clinical Epidemiology.
These teams, with a strong research background in ND and existing active trans-disciplinary local collaborations, will interact, based upon clusters of excellence, with teams issued from “Science and Technologies”, “Human and Social Science”, Economy and Law of BU.
BIND will promote transdisciplinary education through the Bordeaux School of Neuroscience (NENS network), the School of Public Health and the PhD School “SP2”(Societies Politic Public Health).
BIND will also take advantage of a regional cluster in health information systems and technology to promote efficient transfer and valorisation.

 

Bio-sketch



Franc╠žois Tison, aged 53 years, is Professor of Neurology at Bordeaux University (BU)-Consultant Neurologist at the University Hospital of Bordeaux (CHU-B) He is head of the Institute of Neurodegenerative Diseases-clinical branch (IMNc, http://www.imnc-bordeaux.org,) the Memory Clinic (CMRR) and the Motricity Unit at the Department of Clinical Neurology, CHU-B, and adjunct director of the Institute for Neurodegenerative Diseases (IMN, CNRS UMR 5293-http://www.imn-bordeaux.org). He conducted his clinical and research career in the field of neurodegenerative diseases particularly on Parkinson’s disease (PD) and related disorders.

Regarding patient’s care, he created the Movement Disorders Unit at the CHU-B in 1998, the reference center for Huntington’s Disease pre-symptomatic diagnosis in 1994, the multiple system atrophy (MSA) rare disease reference center in 2003, the Regional and Inter- Regional Expert center for PD in 2011, then together with E. Bezard, head of the IMN-CNRS UMR 5293, he developed the IMNc, from 2008 to its opening in 2014, within the Neurocampus investment program. Regarding his research career he explored several fields of basic, translational, epidemiological and clinical research in PD. He contributed to dopaminergic neurotransmission chemical neuro-anatomy in basal ganglia, developed new animal models of atypical parkinsonism (nigrsotriatal degeneration).

He also conducted epidemiological studies on PD and related disorders in population–based cohorts and coordinated as a PI or Co-PI academic (and industry or foundations (MJFF)-sponsored clinical research studies on neuro-pharmacology, physiopathology and biomarkers of PD and AD. Today 30 clinical research studies are running at the IMNc.
He also actively contributes to National or European networks and EC-funded programs (F-CRIN, NS-Park, PD genetics networks, E-MSA Study group, E-Rare). He served on several scientific committees of patient’s associations (PD, MSA, PSP), societies (French Neurological Society and MDS, as a treasurer of E-MDS).

He authored or Co-authored 225 publications, plus 55 as part of a study group, plus 35 textbook chapters (one book edition), H index=42, 6702 citations without self citations, top 10% citation = 9 (2009-14).